ACTBL2 (actin beta-like 2) encodes the seventh actin isoform involved in cell motility and cytoskeletal organization 1. The protein forms complexes with gelsolin and can polymerize, sharing evolutionary origins with non-muscle actins but containing the largest number of non-conserved amino acid substitutions among all actins 1. ACTBL2 is essential for cell motility, influencing invasion, focal adhesion formation, actin polymerization, and lamellipodia/stress fiber formation in melanoma cells 1. The protein is expressed at low levels in most cells, but high expression in specific cell subsets affects cytoskeletal dynamics 1. Clinically, ACTBL2 shows significant disease relevance across multiple cancer types. It is upregulated in colorectal cancer and serves as a novel biomarker 2. In epithelial ovarian cancer, ACTBL2-positive tumor-infiltrating leukocytes, primarily CD8+ T-cells and CD68+ macrophages, are associated with improved overall survival and serve as an independent prognostic factor 3. ACTBL2 is also identified as a potential therapeutic target in thymoma 4 and is regulated by the oncogene CTCFL in ovarian cancer 5. Additionally, ACTBL2 shows promise as a biomarker for schizophrenia diagnosis in proteomic analyses 6.